Answers to Everyday Practice Challenges in HIV Medicine:
A Phone-a-Friend Peer Consult Series—Volume 3
Early experience implementing long-acting injectable cabotegravir/rilpivirine for human immunodeficiency virus-1 treatment at a Ryan White-funded clinic in the US South.
Collins LF, Corbin-Johnson D, Asrat M, et al. Open Forum Infect Dis. 2022;9(9):ofac455.
HIV treatment with dolutegravir and doravirine: rationale for selection and clinical outcomes in a highly treatment experienced population.
Denyer R, Zemskova J, Benator DA. Int J STD AIDS. 2022;33(12):1073-1077.
HIV DNA sequencing to detect archived antiretroviral drug resistance.
Geretti AM, Blanco JL, Marcelin AG, et al. Infect Dis Ther. 2022;11(5):1793-1803.
Weight loss associated with semaglutide treatment among people with HIV.
Haidar L, Crane HM, Nance RM, et al. AIDS. 2023;38(4):531-535.
48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia.
Hickey MD, Gistand N, Grochowski J, et al. Clin Infect Dis. 2025;80(4):864-870.
Tirzepatide once weekly for the treatment of obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387(3):205-216.
Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities.
Liu Y, Cao W, Sun M, et al. Emerg Microbes Infect. 2020;9(1):194-206.
Central nervous system impact of perinatally acquired HIV in adolescents and adults: an update.
Nichols SL. Curr HIV/AIDS Rep. 2022;19(1):121-132.
Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV.
Paton NI, Musaazi J, Kityo C, et al; for the NADIA Trial Team. N Engl J Med. 2021;385(4):330-341.
Long-acting injectable CAB/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359.
Rana AI, Bao Y, Zheng L, et al. Conference on Retroviruses and Opportunistic Infections; March 3-6, 2024; Denver, CO. Abstract 212.
Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection.
Segal-Maurer S, DeJesus E, Stellbrink HJ, et al; for the CAPELLA Study. N Engl J Med. 2022;386(19):1793-1803.
The use of broadly neutralizing antibodies (bNAbs) in HIV-1 treatment and prevention.
Thavarajah JJ, Hønge BL, Wejse CM. Viruses. 2024;16(6):911.
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF, Sokhela S, Simmons B, et al. Lancet HIV. 2020;7(10):e666-e676.
Broadly neutralizing antibodies for human immunodeficiency virus treatment: broad in theory, narrow in reality.
Waters L, de Miguel-Buckley R, Poulin S, et al. Clin Infect Dis. 2023;76(6):1136-1141.
Once-weekly semaglutide in adults with overweight or obesity.
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002.
CLINICAL PRACTICE GUIDELINES
Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel.
Gandhi RT, Landovitz RJ, Sax PE, et al. JAMA. 2024. [Epub ahead of print]
Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA Guidelines Panel.
Sax PE, Thompson MA, Saag MS; IAS-USA Treatment Guidelines Panel. JAMA. 2024;331(12):1060-1061.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services
CLINICIAN RESOURCES
The SSHADESS screening: a strength-based psychosocial assessment
American Academy of Pediatrics
Clinical Guidelines Program: HIV Treatment
New York State Department of Health AIDS Institute
Clinician-to-Clinician Advice
National Clinician Consultation Center; University of California, San Francisco
HIV drug resistance database.
Stanford University.
Recommendations
US Preventive Services Task Force.
PATIENT AND CAREGIVER RESOURCES
AIDSMap
NAM Publications
Living with HIV
Centers for Disease Control and Prevention
National Institutes of Health
Evolving Best Practices for LAI Implementation
Activity 1
| Faculty: | Onyema Ogbuagu, MBBCh, FACP, FIDSA; William R. Short, MD, MPH, FIDSA |
| Release: | 06/27/2025 |
| Expiration: | 06/27/2026 |
Addressing Weight Gain in People With HIV in the GLP-1 RA Era
Activity 2
| Faculty: | Onyema Ogbuagu, MBBCh, FACP, FIDSA; David A. Wohl, MD |
| Release: | 07/11/2025 |
| Expiration: | 07/11/2026 |
The Future of ART: Broadly Neutralizing Antibodies (bNabs) and 2-Drug Regimens
Activity 3
| Faculty: | Laura Waters, MD, FRCP; Paul E. Sax, MD |
| Release: | 07/25/2025 |
| Expiration: | 07/25/2026 |
